PECAM1 and neoplasm: Tanaka et al. [126] have showed that antibodies to CD105 react preferentially with active endothelial cells of angiogenic tissues in neoplasms; on the other hand, antibodies to pan-endothelial antigen (such as CD31 and CD34) may also react with stable vessels trapped in the tumor.